Aktiechat - investeringstips
Aktiesnakken
TESLA
Genmab
NOVO
Bavarian Nordic
Zealand Pharma
Ennogie
Medico
Vestas
Chemometec
Grønne Aktier
Hansa Biopharma
Pharma
AMBU
Shipping
BITCOIN
Forsvarsaktier
GN Store Nord
Gubra
Politiksnakken
Amerikanske aktier
Banker og Finans
Biotek-snakken
Embla Medical
OLIE OG GAS
![]() |
3/11 17:34 af Helge Larsen/PI-redaktør |
This session is over.
|
![]() |
3/11 17:33 af Jan Van de Winkel |
We look forward to returning for Q4 and thank you for all the great and energizing questions..
|
![]() |
3/11 17:33 af Helge Larsen/PI-redaktør |
Thank You for joining us and thank you for the many fullfilling answers to our questions. We look forward to to seeing you back here on ProInvestor.com after Q4.
|
![]() |
3/11 17:32 af Jan Van de Winkel |
We will use the corporate tax rate in Denmark of 22%..
|
![]() |
3/11 17:32 af investor1989 |
What long term tax rate (when all tax loses are used) should we use for genmab going forward ?
|
![]() |
3/11 17:31 af Jan Van de Winkel |
This was to meet our obligations as we had 70,000 RSUs outstanding, this number would also cover near term committments..
|
![]() |
3/11 17:30 af investor1989 |
You bought back 100.000 shares in Q3. Have you some kind of guiding around that going forward or are that an oppurtunistic thing around the share price etc. ?
|
![]() |
3/11 17:30 af Jan Van de Winkel |
Looking forward...
|
![]() |
3/11 17:30 af Helge Larsen/PI-redaktør |
Great. We have 2 questions more left for you. :-)
|
![]() |
3/11 17:29 af Jan Van de Winkel |
We - and Janssen - vigourously dispute that there is patent infringement and therefore we cannot further comment on the litigation..
|
![]() |
3/11 17:28 af jkj |
Regarding the Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States, if Morphosys should be succesful, what will then Genmab obligations ?
|
![]() |
3/11 17:28 af Jan Van de Winkel |
There is a lot of interesting data and we have issued a media release highlighting what we think are key abstracts..
|
![]() |
3/11 17:27 af jkj |
if you should highligt one off your released abstractat for ash, which one should that be ?
|
![]() |
3/11 17:26 af Jan Van de Winkel |
We are entitled to a single digit royalty and milestone payments and we are very pleased to see a blue chip IO player such as BMS actively moving forward with this program..
|
![]() |
3/11 17:25 af GeorgeBest |
After BMS bought Cormorant and thereby HuMax-IL8, has that increased your expectations that IL8 can develope into a meaningful earnings contributer to Genmab?
|
![]() |
3/11 17:25 af Jan Van de Winkel |
This is a productive collaboration but Novo Nordisk is responsible for updates on active programs..
|
![]() |
3/11 17:24 af Joakim Von And |
News on corbaration ( samarbejde ) with Novo ?
|
![]() |
3/11 17:24 af Jan Van de Winkel |
This is a preclinical program, run by Lundbeck so we cannot give further information on this program..
|
![]() |
3/11 17:24 af GeorgeBest |
When do you expect Lundbeck to move into the clinic with the Alzheimer drug licenced from Genmab?
|
![]() |
3/11 17:23 af Jan Van de Winkel |
Next week (at our capital markets day) we will give further clarity on other blood cancer indications..
|
![]() |
3/11 17:22 af Bulder |
Is it your intention to take Daratumumab in the clinic against Acute Myeloid Leukemia?
|
![]() |
3/11 17:22 af Jan Van de Winkel |
No..
|
![]() |
3/11 17:22 af GeorgeBest |
After Novartis stroke a bispecific license deal with Xencor, has that dampened your expectations on Genmabs duobody collaboration with Novartis?
|
![]() |
3/11 17:20 af Jan Van de Winkel |
It is of course more challenging to keep 50% or more of the ownership, but not an obstacle..
|
| ||
![]() |
3/11 17:19 af GeorgeBest |
You have on countless occasions told that Genmab want to keep 50% ownership in new tecknology deals. Is that an obstacle to get new deals concluded?
|
![]() |
3/11 17:19 af Jan Van de Winkel |
We cannot comment on specific partnerships..
|
![]() |
3/11 17:19 af Jan Van de Winkel |
we will talk more about our technologies at our capital markets day next week..
|
![]() |
3/11 17:19 af GeorgeBest |
Is Gilead interested in doing more Duobody/Hexabody license deals, as the ohne they did on HIV?
|
![]() |
3/11 17:18 af Jan Van de Winkel |
We have a number of interactions with pharma and biotech companies for different therapeutic areas...
|
![]() |
3/11 17:18 af GeorgeBest |
Is there any interest from big pharma in Genmabs hexabody platform? So there is no license collaborations published with big pharma?
|
![]() |
3/11 17:17 af Jan Van de Winkel |
Next week we will hold a capital markets day (in NYC but also webcast live and archived on our website). This should shed a lot of light on our preclinical and clinical programs..
|
![]() |
3/11 17:16 af investor1989 |
The two IND you are targeting for 2017. Can you maybe show some more light on timing. First half, summer, second half. etc?
|
![]() |
3/11 17:15 af Jan Van de Winkel |
It is very time consuming and a long process to do deals. We are activating working on the partnering of HexaBody and DuoBody platforms and do expect new agreements in the f
uture..
|
![]() |
3/11 17:14 af investor1989 |
Hexabody partnerships have been slow since this platform was launched. Why that? when launched you talked about inlicense drugs, life cycle management opportunities etc. ?
|
![]() |
3/11 17:14 af Jan Van de Winkel |
Contractually Seattle Genetics can exercise their opt in right at the end of the Phase 1/2 study. This study is ongoing..
|
![]() |
3/11 17:13 af Solsen |
Mr Winkel. Could you sheed some light on when to expect Seattle Geneticts to decide to co-develope or let Genmab going alone on royalty basis with Tisotumab ?
|
![]() |
3/11 17:13 af Jan Van de Winkel |
You can expect combination studies between daratumumab and other key MM agents in the coming time..
|
![]() |
3/11 17:12 af Sukkeralf |
Do Janssen intend to start phase III trials with Daratumumab in combination with Kyprolis (and Ninlaro) to cover all proteasome inhibitor combinations (and making a bit harder for isatuximab) to find a place in the CD38 MM-marked ?
|
![]() |
3/11 17:11 af Jan Van de Winkel |
...the sub cut version would get a different brand name, and likely a different price but that is determined by Janssen..
|
![]() |
3/11 17:11 af Jan Van de Winkel |
this means a royalty between 12-20% of net sales...
|
![]() |
3/11 17:11 af Jan Van de Winkel |
The deal between Genmab and Janssen stays the same (exactly the same royalty as with i/v)...
|
![]() |
3/11 17:10 af Sukkeralf |
If Janssen get sc dosing of daratumumab (via Halozymes technology) approved - could that lower the royalties Genmabs gets or will Halozymes royalty only be deducted fra Janssen ? Would Darzalex then be prices differently due to better convenience (sc dosing) for the patients ?
|
![]() |
3/11 17:09 af Jan Van de Winkel |
..
|
![]() |
3/11 17:09 af Jan Van de Winkel |
As the studies have not yet started and immunomodulatory effects take time to build up, you shouldnt expect data in the near future.
|
![]() |
3/11 17:08 af Solsen |
Mr Winkel. When can we expect the first in human data on the immunomodulatory effect in solid cancer (Darzalex) ?
|
![]() |
3/11 17:07 af Jan Van de Winkel |
This study is announced in a solid tumor and should start shortly.
|
![]() |
3/11 17:06 af Bulder |
Any news about dara + Tecentriq in a solid tumor?
|
![]() |
3/11 17:05 af Jan Van de Winkel |
We feel that daratumumab is an excellent backbone treatment for MM. And that many new agents would be excellent combination partners with daratumumab..
|
![]() |
3/11 17:04 af MrEbbe |
Dear Jan. Congrats, on the great Q3 performance. Could you give us a brief overview of the competitors situations regarding Darzalex. There have been some articles lately with oral tablets among others. How big a thread is these to Darzalex, that takes longer time pr treatment.
|
![]() |
3/11 17:03 af Jan Van de Winkel |
There is a Phase 2 study scheduled for NKT Cell Lymphoma by Janssen so we are enthused by this opportunity and look forward to the data.
|